Boron
8 benefits mapped to clinical evidence across supplements.
Dose per serving from products
3,866 products in our catalogue print how much Boron a serving holds.
Most common: 500 mcg to 1 mg, 25% of 3,866 products.
| Dose per serving | Products |
|---|---|
| 50 mcg or less | 126 |
| 50 mcg to 100 mcg | 72 |
| 100 mcg to 250 mcg | 535 |
| 250 mcg to 500 mcg | 384 |
| 500 mcg to 1 mg | 968 |
| 1 mg to 2.5 mg | 665 |
| 2.5 mg to 5 mg | 661 |
| 5 mg to 10 mg | 360 |
| over 10 mg | 95 |
Dose per serving from research
11 study groups in 7 studies say how much Boron participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 2.5 mg to 5 mg, 45% of 11 study groups.
| Daily dose | Study groups |
|---|---|
| 1 mg or less | 1 |
| 1 mg to 2.5 mg | 0 |
| 2.5 mg to 5 mg | 5 |
| 5 mg to 10 mg | 4 |
| 10 mg to 25 mg | 1 |
Benefit Evidence
Oxygenation up, fatigue down +4.8%
Inflammation down, energy up â42.9 mg/L
Research sources
Skin repair (15)
- Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups
PubMed ID: 31264114
Pooled phaseâIII and longâterm crisaborole data show consistent improvements in disease severity and pruritus across groups â solid topical skin evidence.
- Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis
PubMed ID: 32981097
Pediatric/adolescent pooled analysis: earlier and greater improvements in disease severity and itch with crisaborole â supports topical skin repair in youth.
- Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area
PubMed ID: 32318744
Postâhoc pooled analysis found crisaborole reduced %BSA and improved composite severity (ADSI) vs vehicle â direct skin outcome improvements.
- A phase 2b, randomized, double-blind, multicenter, vehicle-controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2Â years and older with mild-to-moderate atopic dermatitis
PubMed ID: 34435694
Phase 2b Japanese crisaborole study showed reduced eczema signs and itch vs vehicle â topical skin benefit.
- The Preventive Effects of Boron-Based Gel on Radiation Dermatitis in Patients Being Treated for Breast Cancer: A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial
PubMed ID: 34979503
Phase III RCT: topical 3% sodium pentaborate gel dramatically reduced radiation dermatitis, erythema and dry desquamation vs placebo.
- The effect of the boron-based gel on the treatment of diabetic foot ulcers: A prospective, randomized controlled trial
PubMed ID: 37421808
Randomized doubleâblind trial: topical 3% sodium pentaborate gel markedly improved diabetic foot ulcer healing and reduced recurrence (very large absolute effects).
- Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome toward nonlesional and normal skin
PubMed ID: 37054814
Proteomic mechanistic study: topical crisaborole normalized lesional atopic dermatitis proteome and reduced inflammatory pathway markersâmechanistic support for skin repair activity.
- Clinical efficacy evaluation of crisaborole ointment in the treatment of vulvar leukoplakia
PubMed ID: 36820717
Randomized study in vulvar leukoplakia: crisaborole improved lesion scores and symptoms vs placeboâtopical boronâcontaining drug with skin/epithelial benefit.
- Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged â„ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study
PubMed ID: 37184828
52âweek maintenance trial: onceâdaily crisaborole delayed flares and increased flareâfree days vs vehicleâsupports longerâterm topical skin disease control.
- Efficacy and safety of crisaborole ointment, 2%, in participants aged â„45Â years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study
PubMed ID: 38340127
Phase 2a trial in stasis dermatitis: crisaborole improved lesion signs vs vehicleâsupport for topical skin benefit.
- Amorolfine hydrochloride cream and 2% crisaborole ointment: a study on their therapeutic benefits for keratotic tinea pedis
PubMed ID: 40936384
Randomized dermatology trial: adding 2% crisaborole improved clinical response in keratotic tinea pedis â direct evidence of a boron-containing topical improving skin outcomes.
- Efficacy and Safety of Proactive Therapy with 2% Crisaborole Ointment in Children with Mild-to-Moderate Atopic Dermatitis: A Randomized Controlled Study
PubMed ID: 39873962
Proactive crisaborole use reduced flares and steroid rescue in children with ADâsupports preventive skin repair/control with a boronâcontaining topical drug.
- A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis
PubMed ID: 26659931
Crisaborole (a boron-containing topical) produced marked lesion clearance and severity reduction in atopic dermatitis â strong, direct skin-repair / anti-inflammatory evidence.
- Effects of Boron-Based Gel on Radiation-Induced Dermatitis in Breast Cancer: A Double-Blind, Placebo-Controlled Trial
PubMed ID: 27700210
Small randomized trial: boron-based gel reduced radiation-induced skin reactions vs placebo â directly relevant to skin repair/treatment of injury.
- Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial
PubMed ID: 31419544
Intrapatient RCT: crisaborole produced large transcriptomic and biomarker normalization of lesions vs vehicle â strong mechanistic and clinical skin repair signal (topical boron drug).
Inflammation (11)
- Possible therapeutic effects of boron citrate and oleoylethanolamide supplementation in patients with COVID-19: A pilot randomized, double-blind, clinical trial
PubMed ID: 35183882
Boron citrate reduced inflammatory markers (hs-CRP, IL-1ÎČ, IL-6, ESR) in a small randomized COVID-19 trial â direct evidence of anti-inflammatory effects in acute illness.
- A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis
PubMed ID: 26659931
Crisaborole (boron-containing topical PDE4 inhibitor) reduced lesion severity in atopic dermatitis â direct anti-inflammatory skin effect.
- Effects of Boron-Based Gel on Radiation-Induced Dermatitis in Breast Cancer: A Double-Blind, Placebo-Controlled Trial
PubMed ID: 27700210
Boron-based gel reduced radiation dermatitis scores vs placebo â indicates local anti-inflammatory/skin-protective effects.
- Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial
PubMed ID: 31419544
Intrapatient RCT showed crisaborole rapidly normalized inflammatory lesion transcriptomics and biomarkers â strong local antiâinflammatory effect (topical boron drug).
- The Preventive Effects of Boron-Based Gel on Radiation Dermatitis in Patients Being Treated for Breast Cancer: A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial
PubMed ID: 34979503
Phase III RCT: topical 3% sodium pentaborate gel produced large reductions in dermatitis and erythema vs placeboâclinically meaningful antiâinflammatory effects in irradiated skin.
- The effect of the boron-based gel on the treatment of diabetic foot ulcers: A prospective, randomized controlled trial
PubMed ID: 37421808
Topical sodium pentaborate gel greatly improved diabetic foot ulcers and reduced recurrenceâconsistent with antiâinflammatory and woundâhealing effects.
- Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome toward nonlesional and normal skin
PubMed ID: 37054814
Mechanistic proteomic data: crisaborole reduced key inflammatory (Th2/Th17) pathway markers in AD lesionsâstrong molecular evidence for antiâinflammatory action of a boronâcontaining topical drug.
- Clinical efficacy evaluation of crisaborole ointment in the treatment of vulvar leukoplakia
PubMed ID: 36820717
Crisaborole significantly improved lesion scores in vulvar leukoplakia vs placeboâreflects local antiâinflammatory/therapeutic effect.
- Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged â„ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study
PubMed ID: 37184828
Crisaborole maintenance reduced flares and increased flareâfree days vs vehicle in ADâclinical antiâinflammatory disease control over 52 weeks.
- Efficacy and safety of crisaborole ointment, 2%, in participants aged â„45Â years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study
PubMed ID: 38340127
Phase 2a stasis dermatitis trial: crisaborole improved lesion signs vs vehicleâsupports antiâinflammatory topical activity.
- Efficacy and Safety of Proactive Therapy with 2% Crisaborole Ointment in Children with Mild-to-Moderate Atopic Dermatitis: A Randomized Controlled Study
PubMed ID: 39873962
Proactive crisaborole reduced relapse rate and steroid use in pediatric ADâsupports antiâinflammatory/preventive topical activity.
Hair & Nails (4)
- The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis
PubMed ID: 25226015
Dose-ranging topical tavaborole study showed increased nail clearance/negative cultures vs vehicle â direct evidence for nail benefit.
- Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies
PubMed ID: 28521541
Pooled follow-up showed tavaborole yielded substantially higher complete cure and treatment-success rates vs vehicle â meaningful clinical benefit for diseased nails.
- Topical Tavaborole in the Treatment of Onychomycosis Complicated by Dermatophytoma: A Post-hoc Assessment of Phase II Subjects
PubMed ID: 29537453
Phase II onychomycosis trials of tavaborole showed meaningful complete resolution rates versus vehicle for difficult dermatophytoma â strong topical nail benefit, indirect for supplements.
- Tavaborole in Difficult-to-Treat Onychomycosis Cases: A Post-hoc Assessment of Phase III Subjects
PubMed ID: 29036255
Tavaborole (a boron-containing topical) improved complete/near-complete cures in difficult onychomycosis â directly relevant to nail health (treatment of infection, not strengthening per se).
Immune support (3)
- Possible therapeutic effects of boron citrate and oleoylethanolamide supplementation in patients with COVID-19: A pilot randomized, double-blind, clinical trial
PubMed ID: 35183882
Randomized pilot in mildâmoderate COVID-19: boron citrate (with/without OEA) increased lymphocyte counts and improved several biomarkers, consistent with enhanced immune/recovery signals.
- Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial
PubMed ID: 29486041
Meropenemâvaborbactam (contains boron-based inhibitor) showed superior microbial eradication in complicated UTI â direct demonstration that a boron-containing drug can improve infection outcomes (drug-specific, not supplement).
- Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome toward nonlesional and normal skin
PubMed ID: 37054814
Crisaborole proteomic study showed reduction of Th2/Th17 inflammatory pathway markers in lesionsâsuggests modulation of local immune/inflammatory responses in skin.
Bone health (1)
- Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma
PubMed ID: 21366694
Postâhoc VISTA analysis: VMP (bortezomibâcontaining) increased ALP, decreased DKKâ1 and reduced boneârelated progression events â strong direct boneârelated signal in humans (drug includes boron atom, though not dietary boron).
Hormone balance (1)
- Effects of boron supplementation on the severity and duration of pain in primary dysmenorrhea
PubMed ID: 25906949
Randomized, triple-blind trial: oral boron 10 mg/day reduced menstrual pain severity and duration â direct clinical effect on a female reproductive symptom, suggesting influence on female hormone-related physiology.
Mental clarity (1)
- Dietary boron, brain function, and cognitive performance
PubMed ID: 7889884
Across three controlled human studies, low dietary boron consistently produced EEG shifts and slower attention/short-term memory response times â strong evidence of cognitive effects.
Energy & Fatigue (1)
- Possible therapeutic effects of boron citrate and oleoylethanolamide supplementation in patients with COVID-19: A pilot randomized, double-blind, clinical trial
PubMed ID: 35183882
Boron citrate improved oxygen saturation and respiratory rate in COVID-19 patients â objective physiologic changes that could relate to perceived energy.
Similar by evidence
Supplements the same benefits carry qualifying findings for â a fact about the evidence graph, not a recommendation to swap.
Products with Boron
Search all4879 products whose verified label declares Boron â not every bottle that mentions it in a title.
Being studied right now
Recruiting clinical trials registered on ClinicalTrials.gov. A trial in progress has no result yet â this is what the field is asking, not what it found.